Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

SPI2 investigator team

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)988-997
JournalThe Lancet Neurology
Volume19
Issue number12
Early online date23 Oct 2020
DOIs
Publication statusPublished - Dec 2020

Cite this